aliquoting raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-14 and is reviewed periodically as new material appears.
Aseptic technique reduces microbial and particulate contamination when a peptide solution will be used in cell culture or other sensitive applications. Work in a clean area, use sterile containers and filtered tips, and avoid touching vial interiors. Preparing aliquots immediately after dissolution limits repeated temperature cycling, which is a common cause of aggregation and activity loss. Low-binding plastic tubes are preferred for peptides that adsorb to surfaces, especially hydrophobic or positively charged sequences. Labels should record identity, solvent, concentration, and preparation date so that later use can be traced.
Shipping and short-term transfer require attention to temperature control and physical stability. Frozen solutions are commonly sent on dry ice, while lyophilized powders may travel with gel packs or insulated packaging. Thawing should be done slowly on ice or in a refrigerator, not by vigorous heating, and the solution should be mixed gently before use. Temperature loggers can document excursions during transit, but their presence does not prove that a peptide remained stable. Analytical checks such as chromatography or mass spectrometry can verify identity and purity after storage or shipping.
Reconstitution begins with selecting a solvent that dissolves the peptide without causing degradation. Water or aqueous buffer is suitable for many hydrophilic sequences, while hydrophobic peptides may require a small amount of organic solvent such as acetonitrile or dimethyl sulfoxide before dilution. The solvent is added to the vial rather than the powder being scraped out, and the mixture is swirled or inverted gently to avoid foaming. Complete dissolution should be confirmed visually, and insoluble material may indicate aggregation or impurities. Because solvent tolerance varies, published solubility information or a small test dissolution can guide handling.
After reconstitution, dividing the solution into single-use aliquots limits multiple warming and cooling events and reduces contamination risk. Low-binding polypropylene tubes are often preferred because peptides can adsorb to glass or untreated plastic surfaces. Filling headspace with nitrogen or argon can slow oxidation, and amber or foil-wrapped containers reduce photodegradation. Each aliquot should be labeled with peptide identity, concentration, date, and storage conditions. Frozen aliquots should be thawed quickly and kept on ice until use.
When a peptide arrives, the vial should be inspected for damage, and its label, lot number, and accompanying analytical data should be recorded. Cold vials should equilibrate to room temperature before opening to prevent condensation on the powder. Moisture uptake can reduce stability and complicate accurate weighing or reconstitution. Inventory systems that track date, quantity, and storage location help prevent unnecessary temperature cycling. Personnel should follow institutional or manufacturer instructions for any specific peptide.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder or frozen solution | Powder typically more stable for long-term storage; solutions require colder conditions. |
| Recommended reconstitution solvent | Water, buffer, or water-miscible organic solvent | Matches peptide hydrophobicity; test small portion if unknown. |
| Typical working aliquot size | Single-use volumes in low-binding tubes | Reduces repeated warming and cooling and contamination risk. |
| Short-term shipping condition | Dry ice for frozen solutions; gel packs for powders | Insulation and temperature logging help document transit. |
| Common purity check | Reverse-phase HPLC with UV detection | Often paired with mass spectrometry for identity confirmation. |
Temperature is a primary variable because most degradation reactions slow as thermal energy decreases. Lyophilized powders are commonly held at -20 °C for routine work and at -80 °C for longer archival periods, though exact recommendations depend on the peptide. Solutions are less stable than dry powders in many cases, and repeated freeze-thaw cycles can promote aggregation or precipitation. Inert atmospheres, such as argon or nitrogen, can limit oxidation for oxygen-sensitive sequences. Desiccants reduce water activity, which lowers hydrolysis rates during storage.
Light exposure can damage aromatic residues and certain labels, so amber vials or opaque containers are often used. pH control matters in solution, as extreme acidity or alkalinity accelerates backbone cleavage; buffers may also introduce ions that affect solubility. Microbial growth is a concern for aqueous preparations that lack preservatives, though many research peptides are handled in sterile or low-bioburden conditions. Container materials can adsorb peptides, particularly hydrophobic or positively charged sequences, reducing recovery. These factors interact, meaning storage decisions balance chemical stability, physical state, and intended use.
Peptides are short chains of amino acids linked by amide bonds. Their stability depends on sequence, length, and the chemical environment. Common degradation routes include hydrolysis of the peptide backbone, oxidation of methionine or cysteine residues, deamidation of asparagine or glutamine, and aggregation through hydrophobic or electrostatic interactions. These processes can alter mass, charge, or biological activity, so storage conditions aim to slow them. The relative importance of each route varies widely among peptides.
Water is a central factor in peptide degradation because it enables hydrolysis and mobilizes reactive species. Lyophilized or dry powders typically remain stable for longer than solutions when kept cool and dry. Oxygen can drive oxidation, particularly for sulfur-containing residues, while light can catalyze side-chain damage. Buffer choice and pH influence charge state and can accelerate or slow deamidation and aggregation. Freeze-thaw cycles may concentrate solutes or promote ice-induced aggregation, so minimizing such cycles is a common handling goal.
Temperature selection balances degradation rate against physical changes. Many lyophilized peptides are stored at -20 °C, while some modified or longer sequences require -80 °C for extended periods. Aqueous stock solutions are less stable and are often kept at -20 °C or below in single-use aliquots. Repeated freeze-thaw cycles can cause aggregation, precipitation, or loss of activity, so aliquoting before freezing reduces that risk. Frost-free freezers cycle above freezing and may be unsuitable for long-term peptide storage.
Container and environment choices matter. Peptides may adsorb to glass, plastic, or filter membranes, especially at low concentrations. Low-binding tubes and inert containers reduce loss. Moisture barriers include sealed bags with desiccant, and light protection uses amber vials or opaque wraps. Inert gas blankets can limit oxidation for sequences containing methionine, cysteine, or tryptophan. Buffers and pH also affect solution stability; extremes of pH accelerate hydrolysis and deamidation. These practices apply to research and manufacturing settings, not to any specific clinical use.
Peptides are short amino acid polymers whose stability depends on sequence, length, and chemical modifications. In dry form, most peptides are relatively stable because low water activity slows hydrolysis and other degradation. Residual moisture, oxygen, and light can still promote oxidation, deamidation, or aggregation over time. Storage recommendations therefore usually combine low temperature, desiccation, and protection from light. Because each peptide has distinct properties, no single condition fits every sequence.
Peptides are short chains of amino acids linked by amide bonds, and their storage stability depends on sequence, length, and three-dimensional structure. Chemical degradation can occur through hydrolysis, oxidation, deamidation, and aggregation, while physical changes such as precipitation or surface adsorption reduce recovery. Storage conditions are chosen to slow these processes without altering the peptide itself. Because peptides vary widely, no single condition suits every sequence, so laboratories often establish stability empirically for each batch.
Temperature is a primary factor because most degradation reactions proceed more slowly at lower temperatures. Lyophilized peptides are commonly held at -20 °C or below, although some sequences remain stable at 2–8 °C for limited periods. Moisture uptake during handling can accelerate hydrolysis, so sealed containers and desiccants are used. Solutions are generally less stable than powders and may require freezing at -80 °C or refrigeration, depending on the peptide. Repeated freeze-thaw cycles can promote aggregation even when the storage temperature is otherwise suitable.
Light, oxygen, and pH influence peptide integrity through specific side-chain reactions. Methionine and cysteine residues are susceptible to oxidation, and tryptophan can degrade under strong light. Inert gas overlays and amber glass or opaque containers reduce these risks. pH affects charge, solubility, and the rate of deamidation or aggregation; a value that minimizes one pathway may increase another. The optimal pH and buffer for a given peptide are often determined experimentally, and open questions remain about predicting stability from sequence alone.
Lisdexamfetamine (Vyvanse, others) is an amphetamine-type medication, sold for use in treating ADHD. Its effects typically last around 14 hours. Lisdexamfetamine is inactive on its own and is metabolized into dextroamphetamine in the body. Consequently, it has a lower abuse potential (i.e., reduced effects from parenteral administration).
Tom Kempinski, playwright and screenwriter Peter Kosminsky (born 21 April 1956); writer, playwright, scriptwriter and screenwriter director and producer; has directed Hollywood movies White Oleander and television films, Warriors, The Government Inspector, The Promise, Wolf Hall and The State; born in London in 1956 to Jewish parents. Hyam Maccoby (Hebrew: חיים מכובי, 1924–2004) was a Jewish-British scholar, dramatist, playwright and author of over fifteen scholarly books, specialising in the study of the Jewish and Christian religious traditions. He was known for his theories of the historical Jesus and the origins of Christianity. Maccoby's play The Disputation has been widely performed, and was broadcast by Channel 4 starring Christopher Lee and Toyah Willcox. Hyam Maccoby's daughter is the anti-Zionist BDS activist, organiser of Jews for Justice for Palestinians and author, Deborah Maccoby, acknowledged for her monograph on Isaac Rosenberg. Patrick Marber, playwright and comedian Laurence Marks (British writer) (born 8 December 1948), producer, scriptwriter, screenwriter and one half of writing duo Marks and Gran (with Maurice Gran). Harold Pinter, Nobel prize-winning playwright; Pinter signed the mission statement of Jews for Justice for Palestinians in 2005 and its full-page advertisement, "What Is Israel Doing? A Call by Jews in Britain", published in The Times on 6 July 2006, and he was a patron of the Palestine Festival of Literature. In April 2008, Pinter signed the statement "We're not celebrating Israel's anniversary".
=== Blood banking === Blood banking is a concentration within a clinical laboratory that analyzes specimens from potential transfusion recipients and provides compatible blood products to the healthcare team in charge of that patient's care. Several routine tests are performed including blood typing (determination of ABO/Rh status), antibody screening, serologic cross-matching, direct antiglobulin testing, and antibody identification. Beyond the presence of naturally occurring antibodies (isohemagglutinins) to the ABO and Rh(D) blood group antigens, additional immune-stimulated antibodies are considered unexpected alloantibodies. The identification of unexpected antibodies is a labor-intensive process, and sometimes requires the addition of special laboratory techniques to aid in the proper identification of the antibody. Among these techniques are elutions, adsorptions, and enzyme treatment. Some patients produce antibodies to high frequency antigens. That is, the red cell antigens are present in a significant portion of the human population. It may be questionable and very difficult to assess if the antibody is considered clinically significant or not. A clinically significant antibody is an antibody that is capable of causing in vitro hemolysis or a decreased survival of transfused donor red blood cells. Antibodies to high frequency antigens can be assessed for clinical significance using the monocyte monolayer assay.
Isotonitazepyne (N-pyrrolidino-isotonitazene, NPI) is a benzimidazole derivative with potent opioid effects, which has been sold as a designer drug over the internet. Its in vitro potency is approximately 1000 times that of morphine. One sample of counterfeit oxycodone pills were found to contain between 3.3 and 3.5 mg of NPI per pill and no oxycodone.
Other studies have similarly found relatively high absolute testosterone levels with NSAAs in young males. For instance, one study administering flutamide to late-pubertal males found that total testosterone levels increased from 729 ng/dL at baseline to 991 ng/dL with flutamide (+34%).
Sources: en.wikipedia.org
The National Medical Products Administration is not responsible for regulating pharmaceutical ingredients manufactured and exported by chemical companies. This regulatory lack, which has resulted in considerable international news coverage unfavorable to China, has been known for a decade, but failure of Chinese regulatory agencies to cooperate has prevented improvement. In May 2005, the Chinese press agency Xinhua reported that the World Health Organization had established Rapid Alert System, the world's first web-based system for tracking the activities of drug counterfeiters, in light of the increasing severity of the problem of counterfeit drugs.
Breeding crops resistant, or at least less susceptible, to pest attacks. Releasing predators, parasitoids, or pathogens to control pest populations as a form of biological control. Chemical control like releasing pheromones into the field to confuse the insects into not being able to find mates and reproduce. Integrated Pest Management: using multiple techniques in tandem to achieve optimal results. Push-pull technique: intercropping with a "push" crop that repels the pest, and planting a "pull" crop on the boundary that attracts and traps it.
== Production == Plans to create a Nick Fury live action production were circulated as early as September 1986, but it was not until mid-May 1995 that Fox Broadcasting announced the acquisition from New World Entertainment of a Nick Fury series pilot, to be broadcast in 1996. The film was originally sold to Paramount Pictures, with Debra Hill and Lynda Obst as producers, Greg Pruss to write and Stephen Herek originally attached to direct. The teleplay was written by David S. Goyer several years before the film was made, and Goyer was not otherwise involved as he was working on the television series Sleepwalkers. Despite some misgivings within the studio, the producers cast David Hasselhoff in the lead role "to give SHIELD some recognizable star power". The production also markedly "respected and utilized the comic roots of the project", incorporating "a who's who of the Marvel spy scene" and retaining details such as Fury's eyepatch. Goyer was not enthusiastic about the casting of David Hasselhoff, but in hindsight said, "Hasselhoff turned out to be the best thing in it. He got the joke. The script was meant to be very tongue in cheek, and Hasselhoff understood that. Goyer described the film overall as "pretty mediocre". Hasselhoff was reportedly signed for five additional Nick Fury television films, which did not materialize. Shooting for the project occurred between May and June 1997 in Vancouver, British Columbia, Canada.
These properties, along with the reduction of oxidative stress and the re-establishment of glutamatergic balance, would lead to an increase in growth factors, such as brain-derived neurotrophic factor (BDNF), and the regulation of neuronal cell death through B-cell lymphoma 2 (BLC-2) expression. Catabolism to cysteine and cystine cannot fully explain the pharmacology of acetylcysteine. Recent work has shown that acetylcysteine can act as a rapid antioxidant via conversion to hydrogen sulfide and hydropersulfides, independent of glutathione elevation. As mentioned before, acetylcysteine clears mucus by opening disulfide bonds.
Sources: en.wikipedia.org
=== Other lymphomas and squamous-cell carcinoma === In September 2022, the FDA announced new information regarding other types of cancers related to breast implants, based on medical device reports (MDRs) of cases of patients with squamous-cell carcinoma or various lymphomas found in the scar tissue around breast implants. The agency reported 10 MDRs about squamous-sell carcinoma found in the capsule scar tissue and 12 MDRs about various lymphomas also in the scar tissue around the breast implants. These new cases do not overlap with cases of BIA-ALCL. SCC and other lymphomas have been found in smooth-surface and textured implants as well as silicone-gel-filled and saline-filled implants. Patients who reported symptoms specified swelling, pain, lumps, and changes to their skin. As of 2022, neither the incidence rate nor prevalence is known.
== Clinical significance == FAP expression is seen on activated stromal fibroblasts of more than 90% of all human carcinomas. Stromal fibroblasts play an important role in the development, growth and metastasis of carcinomas. Several approaches to FAP targeting in cancer diagnosis and treatment are currently being tested. In diagnostic imaging radiolabeled FAP inhibitors (FAPIs) are used as PET tracers to visualize tumors. Therapeutic approaches include the use of low molecular weight inhibitors, prodrugs activated by FAP, various anti-FAP antibodies and their conjugates, FAP-CAR T cells, and FAP vaccines. By cleaving FGF-21, FAP is also thought to play a possible role in energy metabolism. Talabostat is an inhibitor of FAP and related enzymes, for which clinical trials have been done, but further research is suspended. Sibrotuzumab is a monoclonal antibody against FAP.
Currently there is no universal method to overcome the problems of delivery, cell uptake and endosomal escape, but there exist several approaches which are tailored to specific cells and their receptors. A conjugation of ON therapeutics to an entity responsible for cell recognition/uptake not only increases the uptake (vide supra) but is also believed to decrease the complexity of the cell uptake as mainly one (ideally known) mechanism is then involved. This has been achieved with small molecule-ON conjugates for example bearing an N-acetyl galactosamine which targets receptors of hepatocytes. These conjugates are an excellent example for obtaining an increased cell uptake paired with targeted delivery as the corresponding receptors are overexpressed on the target cells leading to a targeted therapeutic (compare antibody-drug conjugates which exploit overexpressed receptors on cancer cells). Another broadly used and heavily investigated entity for targeted delivery and increased cell uptake of oligonucleotides are antibodies.
Sources: en.wikipedia.org
Multiple freezing and thawing events can cause aggregation, precipitation, or loss of soluble peptide. Dividing a solution into single-use aliquots before freezing reduces this risk. If multiple cycles are unavoidable, stability should be checked after thawing.
Low-binding polypropylene tubes are often used because some peptides adsorb to glass or standard plastic. The choice depends on peptide hydrophobicity and charge. Containers should be clean, sterile when needed, and compatible with the solvent.
Reverse-phase chromatography can assess purity and retention time, while mass spectrometry confirms molecular mass. These methods can detect degradation products and sequence-related impurities. Results are compared with a reference sample or initial analysis.
Dividing a stock into single-use portions usually reduces multiple thawing and refreezing events and lowers contamination risk. It also allows a needed amount to be removed without warming the entire supply.